Article
If your turnover on a rolling 3-year average reaches 20%, you will need to explore how you contribute to this.
Leveraging the full potential of APPs: Mark Edney, MD, on tips for successful collaboration
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Illuccix approved in Europe for detection of PSMA-positive lesions
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
Addition of PSMA PET led to notable stage migration in mHSPC, study shows
Anktiva targets expanded indication in US and global approvals in EU and UK